ArticleCancer discovery2018
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.
0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 182 citations in OpenAlex.
- A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2022Trial
- Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Nature medicine · 2021Trial
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.Nature communications · 2021Trial
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.Cancer discovery · 2019Trial
- BAP1 Loss in Pleural Mesothelioma Is Associated With Reduced Soluble CCL2 in Patient Effusion, Abrogated CCL2-Mediated Monocyte Recruitment In Vitro.JTO clinical and research reports · 2026Article
- Integrative analysis of single-cell multi-omics reveals heterogeneity in piriform cortex principal neurons and their selective vulnerability in Alzheimer's disease.Clinical and translational medicine · 2026Article
- Article
- PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis andScience advances · 2026Article
- BAP1 Loss as a Marker of Aggressive Clear Cell Renal Cell Carcinoma: Three Cases With Spinal Metastases.Cureus · 2025Article
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- Determinants of late metastases in renal cell carcinoma.Journal of the National Cancer Institute · 2025Article
- Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets.Nature communications · 2025Article
- BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives.Cancers · 2025Review
- An overview of BAP1 biological functions and current therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial.Nature communications · 2025Article
- Identification and Experimental Validation of Prognostic Signature and Peroxisome-Related Key Genes in Clear Cell Renal Cell Carcinoma.International journal of general medicine · 2025Article
- The fall of the genome protectors triad: PBRM1, SETD2, and BAP1's impact on metabolism and immunity in clear cell renal cell carcinoma.Frontiers in cell and developmental biology · 2025Review
- Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis.Biology direct · 2024Article
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 2 countries.
Tao WangQuantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas. Tao.Wang@UTSouthwestern.edu James.Brugarolas@UTSouthwestern.edu seshagiri.somasekar@gene.com.
Rong Lu *Quantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.
Payal Kapur *Kidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Bijay S Jaiswal *Molecular Biology Department, Genentech, Inc., South San Francisco, California.
Raquibul HannanKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ze ZhangQuantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.
Ivan PedrosaKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Jason J LukeDepartment of Medicine, University of Chicago, Chicago, Illinois.
He ZhangBioinformatics Core Facility, The University of Texas Southwestern Medical Center, Dallas, Texas.
Leonard D GoldsteinMolecular Biology Department, Genentech, Inc., South San Francisco, California.
Qurratulain YousufKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Yi-Feng GuKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Tiffani McKenzieKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Allison JoyceKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Min S KimKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Xinlei WangDepartment of Statistical Science, Southern Methodist University, Dallas, Texas.
Danni LuoBioinformatics Core Facility, The University of Texas Southwestern Medical Center, Dallas, Texas.
Oreoluwa OnaboluKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Christina StevensKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.
Zhiqun XieQuantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-7163-7242
Mingyi ChenDepartment of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Alexander FilatenkovDepartment of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Jose TorrealbaDepartment of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas.
Xin LuoBioinformatics Core Facility, The University of Texas Southwestern Medical Center, Dallas, Texas.
Wenbin GuoQuantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.
Jingxuan HeQuantitative Biomedical Research Center, Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas.
Eric StawiskiMolecular Biology Department, Genentech, Inc., South San Francisco, California.
Zora ModrusanMolecular Biology Department, Genentech, Inc., South San Francisco, California.
Steffen DurinckMolecular Biology Department, Genentech, Inc., South San Francisco, California.
Somasekar SeshagiriMolecular Biology Department, Genentech, Inc., South San Francisco, California. Tao.Wang@UTSouthwestern.edu James.Brugarolas@UTSouthwestern.edu seshagiri.somasekar@gene.com.
James BrugarolasKidney Cancer Program, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas. Tao.Wang@UTSouthwestern.edu James.Brugarolas@UTSouthwestern.edu seshagiri.somasekar@gene.com.
The University of Texas Southwestern Medical Center · USIntermolecular (United States) · USSouthern Methodist University · USSouthwestern Medical Center · USUniversity of Illinois Chicago · US
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7MUniversity of Texas Southwestern Medical Center SPORE in Kidney CancerP50CA196516 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI James Brugarolas · 2016 to 2026
$24.7MUT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5MNON-INVASIVE PHYSIOLOGIC PREDICTORS OF AGGRESSIVENESS IN RENAL CELL CARCINOMAR01CA154475 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI PEDROSA, IVAN · 2011 to 2024
$4.3MEvaluation of the BAP1 tumor suppressor gene in renal cell carcinomaR01CA175754 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BRUGAROLAS, JAMES · 2014 to 2018
$1.6MHighly Reactive Hydrazone Chemistry: Orthogonal Modification in Cellular ContextsR01GM110050 · NIGMS · STANFORD UNIVERSITY · PI KOOL, ERIC T. · 2015 to 2018
$1.2MWisdom of Crowds: Integrating Gene Set Enrichment Studies Involving RNA-Seq.R15GM113157 · NIGMS · SOUTHERN METHODIST UNIVERSITY · PI WANG, XINLEI · 2015 to 2015
$356kDevelopment of integrative models for early liver toxicity assessmentR03ES026397 · NIEHS · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, TAO · 2016 to 2017
$162kNCATS NIH HHS UL1 TR001105NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA196516NCI NIH HHS R01 CA154475NCI NIH HHS R01 CA175754NIEHS NIH HHS R03 ES026397NIGMS NIH HHS R01 GM110050NIGMS NIH HHS R15 GM113157
Abstract
By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found that 65% of previously defined immune signature genes are not abundantly expressed in renal cell carcinoma (RCC) and identified 610 novel immune/stromal transcripts. Using eTME, genomics, pathology, and medical record data involving >1,000 patients, we established an inflamed pan-RCC subtype (IS) enriched for regulatory T cells, natural killer cells, T
Indexed as
Gene Regulatory NetworksAnimalsCarcinoma, Renal CellCluster AnalysisExome SequencingGene Expression ProfilingGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansInflammationKidney NeoplasmsMiceNeoplasm TransplantationPrognosisSequence Analysis, RNASurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.